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Incidence and factors associated with geographical relocation in patients
receiving renal replacement therapy
Abstract
BACKGROUND: Renal replacement therapy (RRT) places a burden on patients, and geographical
relocation for easier access to healthcare facilities is a necessity for some. Incidence and factors
associated with relocation has not been comprehensively examined at a national level. We aimed to
determine proportion, incidence, characteristics of RRT patients who relocate and relocation rate by
remoteness of residence and dialysis modality. METHODS: Retrospective cohort analysis using Australian
and New Zealand Dialysis and Transplant Registry to examine RRT patients in Australia from January
2005 to December 2015. Relocation incidence was calculated for remoteness of residence and RRT
modality as rate per 100 patient years. Factors associated with relocation were examined using
competing risk regression models with death as a competing event. RESULTS: Of 24,676 incident patients
on RRT, 5888 (23.9%) relocated with a median time of 1.6 years [IQR 0.7-3.4] years. Relocation incidence
was 7.9 per 100 patient years and increased from major cities to very remote regions (7.2 to 48.8 per 100
patient years respectively, p < 0.001). Remoteness of residence was associated with geographical
relocation in competing risk analysis especially in remote (SHR 1.20, 95%CI 1.01, 1.41 p = 0.034) and very
remote regions (SHR 3.51 95% 3.05, 4.04 p < 0.001). Aboriginal or Torres Strait Islander ethnicity,
compared to Caucasian, was independently associated with relocation (SHR 1.18, 95% CI 1.06,1.31, p =
0.002) while transplant patients were less likely to relocate compared to haemodialysis patients (HR 0.37,
95%CI 0.34, 0.39, p < 0.001). CONCLUSIONS: Relocation in patients receiving RRT is associated with
remoteness of residence, RRT modality and ethnicity. Reasons for relocation and its impact on patient
wellbeing and outcome should be further explored.
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geographical relocation in patients
receiving renal replacement therapy
Hicham I Cheikh Hassan1,2* , Jenny HC Chen1,2,3 and Karumathil Murali1

Abstract
Background: Renal replacement therapy (RRT) places a burden on patients, and geographical relocation for easier
access to healthcare facilities is a necessity for some. Incidence and factors associated with relocation has not been
comprehensively examined at a national level. We aimed to determine proportion, incidence, characteristics of RRT
patients who relocate and relocation rate by remoteness of residence and dialysis modality.
Methods: Retrospective cohort analysis using Australian and New Zealand Dialysis and Transplant Registry to
examine RRT patients in Australia from January 2005 to December 2015. Relocation incidence was calculated for
remoteness of residence and RRT modality as rate per 100 patient years. Factors associated with relocation were
examined using competing risk regression models with death as a competing event.
Results: Of 24,676 incident patients on RRT, 5888 (23.9%) relocated with a median time of 1.6 years [IQR 0.7–3.4]
years. Relocation incidence was 7.9 per 100 patient years and increased from major cities to very remote regions
(7.2 to 48.8 per 100 patient years respectively, p < 0.001). Remoteness of residence was associated with
geographical relocation in competing risk analysis especially in remote (SHR 1.20, 95%CI 1.01, 1.41 p = 0.034) and
very remote regions (SHR 3.51 95% 3.05, 4.04 p < 0.001). Aboriginal or Torres Strait Islander ethnicity, compared to
Caucasian, was independently associated with relocation (SHR 1.18, 95% CI 1.06,1.31, p = 0.002) while transplant
patients were less likely to relocate compared to haemodialysis patients (HR 0.37, 95%CI 0.34, 0.39, p < 0.001).
Conclusions: Relocation in patients receiving RRT is associated with remoteness of residence, RRT modality and
ethnicity. Reasons for relocation and its impact on patient wellbeing and outcome should be further explored.
Keywords: End stage kidney disease, Renal replacement therapy, Geographic relocation, Patient impact, Healthcare
access

Background
Globally, the number of people requiring renal replacement therapy (RRT) is rising [1]. RRT places a high burden on health resources in the form of regular clinic
appointments, investigations, interventions and routine
dialysis attendance in specialised centres. Given the
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complexity of RRT treatment many patients find themselves facing factors necessitating a need to geographically relocate.
Relocation in patients receiving RRT has not been studied extensively. Observational studies have shown that increased travel time to a treatment center for
haemodialysis (HD) is associated with lower HD prevalence, poorer quality of life and higher all-cause mortality
[2–6]. Another factor associated with relocation is access
to treatment by remoteness of residence. In Australia,
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rural and regional residents with chronic diseases had
fewer physician visits, more difficulty accessing health services and a higher mortality compared to their urban
counterparts [7–10]. RRT patients who lived in regional
districts, compared to patients in urban centers, used a
lower proportion of dialysis care and had worse survival
[4, 5, 11, 12]. Both the travel time and access to healthcare
are potential reasons for the lower prevalence of dialysis
in rural Australia compared to major cities [4, 12].
While relocation offers health benefits and easier
access to health services, it also causes significant stress
on the patient and family. Patients who relocated from
rural areas for better health care access often face separation from family, lack of social support and financial
burdens [13, 14]. Dialysis patients who relocated described a decline in willingness to maintain treatment
regimens [15]. The final decision to relocate is likely to
involve a trade-off between benefits of being closer to
family, friends and a familiar social environment (favouring non-relocation) and health benefits of being closer
to a treatment centre in a major health centre (favouring
relocation).
The aims of our study were three-fold. Firstly, we examined characteristics of patients with end-stage kidney
disease who relocated and who did not relocate after
commencement of RRT. Secondly, we assessed the incidence and pattern of relocation between metropolitan,
rural and remote areas. Lastly, we determined the association between geographical remoteness and RRT modality with relocation rates.

Methods
Study design and setting

We conducted a retrospective cohort study using the
Australia and New Zealand Dialysis and Transplant
Registry (ANZDATA). ANZDATA collects yearly information (ending December 31) on all receiving RRT in
Australia and New Zealand. Notification of RRT modality change, treatment centre change and death occurs in
real time. Permission to analyse the data was granted by
the ANZDATA executive. Only de-identified data were
analysed, and the need for informed consent was waived.
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start date and postcode documentation date and patients
who relocated to or from an overseas location.

Data collection

Baseline patient characteristics were collected at the initiation of RRT and included age, gender, ethnicity, comorbidity and cause of renal disease. Comorbidities
recorded include: diabetes, peripheral vascular disease,
chronic lung disease, coronary artery disease and cerebrovascular disease. Ethnicity was classified as Caucasian, Asian, Aboriginal and Torres Strait Islander
(ATSI), Maori-Pacific Islander (MPI) and Other. Causes
of renal disease were classified as glomerulonephritis,
diabetes, hypertension, cystic disease and other.
RRT modality was categorised as transplant, home
therapies and facility HD at the start of initiating RRT
and at the end of the study period (first relocation or
censoring). We combined peritoneal dialysis and home
HD since both belong to the same the category of
home-based therapies and have similar implications for
relocation. If treatment centre or state changed in the
year of relocation, then the RRT modality at the time of
change was chosen. If RRT modality changed during the
year of relocation, then the newer RRT modality was
chosen if RRT modality changed in the first 6 months of
the year and the older RRT modality if the change occurred in the second 6 months of the year. For patients
who did not relocate we assigned the RRT modality at
censoring.
Remoteness of residence was determined from the
postcode using the Accessibility/ Remoteness Index of
Australia taken from the Australia Bureau of Statistics
using Australian Standard Geographical Classification
from the 2011 census data [16]. There are five classes of
major city, inner regional, outer regional, remote and
very remote based on physical road distance from a location to the nearest urban centre. We also further examined relocations from and to major city by change of
state, which would indicate that a relocation occurred to
a new city compared to within the same city.

Exposure factor
Participants

Adult (≥18 years) patients who initiated RRT in Australia
between January 12,005 and December 31,2015, were
alive or remained on RRT for > 6 months and who did
not recover renal function were included in the study.
The year 2005 was chosen since postcode information
was recorded from 2005 onwards on a yearly basis at the
end of the calendar year. We excluded New Zealand patients (due to incomplete postcode information), patients
with no postcode history, those with > 6 months between

Geographical relocation was defined as the first change
in postcode. Postcode was captured by ANZDATA at
the end of the calendar year (December 31st) while
treatment centre or state change occurred in real time.
Relocation date was set as end of the calendar year. If a
treatment centre, state change or death occurred in the
same year as a geographical relocation, then the exact
date was used as the relocation date. Patients were censored on death, loss of follow-up or on reaching end of
study period.
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Statistical analysis

Geographical relocation

Categorical data were expressed as number (percentage) and analysed using chi-square. Continuous data
were was expressed as mean (standard deviation) or
median (interquartile range) and analysed as per distribution. Incidence was calculated as the number of
relocations divided by total patient years. We calculated the incidence for the total cohort, by remoteness of residence and by RRT modality as rate per
100 patient-years. Incidence of net patient gain or
loss due to relocation for each remoteness of residence category was calculated from the difference between the total number of patients relocating to and
leaving the remoteness of residence and dividing by
the total patient years for the remoteness of residence. Factors associated with relocation were examined by fitting Cox proportional hazards models and
competing risk analysis. A multivariable Cox proportional hazards model for time from RRT commencement to the first relocation was constructed using a
backward selection procedure. Covariates with p-value
≤0.2 in the univariate analyses were included in the
model. Interaction between remoteness of residence
and ethnicity was tested using Wald test and found
not to be significant (p = 0.7). Proportional hazards
assumptions were confirmed graphically by plotting
the Schoenfeld’s residuals. We also used Fine-Gray’s
extension of the Cox proportional hazards model to
fit competing risk regression models using death as a
competing event. The covariates for Cox proportional
hazards models and competing risk analysis were the
same. Remoteness of residence and ethnicity were included in all models for their previously established
associations. Results were expressed as hazard ratio
(HR) and sub-hazard ratio (SHR) with 95% confidence
interval (95%CI). We used listwise deletion to handle
missing data. Statistical analysis was preformed using
Stata (version 14.0).

Patients who relocated were more likely, when compared to
those who did not relocate, to be younger (55.4 vs 61.8 years,
p < 0.001), of ATSI background (19.3% vs 8.3%, p < 0.001)
and be from a remote (3.7% vs 2.2%, p < 0.001) or very remote area (9.7% vs 1.5%, p < 0.001) (Table 1). The median
time to relocation was 1.6 [IQR, 0.7–3.4] years (Table 2).
Time from RRT commencement to relocation is shorter in
patients from an ATSI background (p < 0.001), with a comorbidity (1.5 vs 2.1 years, p < 0.001) and who received facility
HD compared to home therapies and transplant (1.4 vs 1.5 vs
3.9 years, respectively, p < 0.001). Time to relocation is also
shorter as remoteness of residence changed from major city
to very remote areas (2.0 vs 0.6 years, p for trend < 0.001).

Results
Of the 30,188 adult patients who commenced RRT from
2005 to 2015, the following patients were excluded: 5160
from New Zealand, 87 with no postcode history, 19 who
had no postcode history for > 6 months and 246 who
relocated from or to overseas. In total 24,676 incident
patients commenced RRT in Australia between 2005
and 2015, 5888 (23.9%) patients relocated and 18,788
(76.1%) did not. The patients were followed-up for a median [IQR] time of 2.2 [0.8,4.5] years with total followup time of 74,039.7 patient years. The study population
was predominantly Caucasian (74.1%) with mean (SD)
age of 60.3 (15.4) years and a high prevalence of comorbidities (65.8%) (Table 1). Most started RRT on facility
HD (70.4%) and lived in a major city (66.6%).

Incidence and pattern of geographical relocation

Incidence of relocation in the total RRT cohort was 7.9
per 100 patient years (95% CI 7.4–8.5). Incidence increased across remoteness of residence within each geographical area reaching in major city 7.2 per 100 patient
years (95% CI 6.6–7.8), in inner regional areas 5.9 per
100 patient years (95% CI 4.8–7.1), in outer regional
areas 8.6 per 100 patient years (95% CI 6.9–10.3), in remote areas 13.5 per 100 patient years (95% CI 9.8–17.2)
and in very remote areas 48.8 per 100 patient years (95%
CI 45.6–51.9) (p < 0.001). Most relocations (4083, 70.6%)
occurred within same remoteness of residence (Table 3)
with more than half the relocations (56.5%) occurring
within major cities (incidence 4.4 per 100 patient years).
For within major city relocation only 7.4% were accompanied with a change of state indicating that more than
90% of major city to major city relocations occurred in
the same city.
Relocation rate by RRT modality increased from 5.4
per 100 patient years (95% CI 4.9–5.7) for transplant, 7.3
per 100 patient years (95%CI 6.9–7.7) for home therapies to 9.4 per 100 patient (95% CI 9.1–9.7) years for facility HD (p < 0.001).
For all RRT patients the net relocation by remoteness of
residence was a gain of 0.12 per 100 patient years for
major cities, 0.12 per 100 patient years for inner regional,
0.24 per 100 patient years for outer regional and 0.13 per
100 patient years for remote. There was a net loss of 0.65
per 100 patient years for very remote regions.
Factors associated with geographical relocation

Variables associated with relocation was determined
using Cox proportional hazard models (Table 4). A
strong association was found for ethnicity, RRT at relocation and remoteness of residence. This remained the
case in the competing risk analysis with transplant associated with a lower risk compared to facility HD as the
RRT modality (SHR 0.37, 95%CI 0.34–0.40, p < 0.001)
(Fig. 1). Ethnicity and remoteness of residence remained
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Table 1 Baseline characteristics of study cohort with comparison between the relocation and non-relocation group
All patients (n = 24,676)

Relocation (n = 5888,23.9%)

Non-relocation (n = 18,788, 76.1%)

Gender (Male)

15,172 (61.5%)

3498 (59.4%)

11,674 (62.1%)

Age (years)

60.3 (15.4)

55.4 (16.2)

61.8 (14.8)

Caucasian

18,142 (74.1%)

3876 (66.0%)

14,266 (76.6%)

Asian

2274 (9.3%)

517 (8.8%)

1757 (9.4%)

ATSI

2669 (10.9%)

1131 (19.3%)

1538 (8.3%)

Race

MPI

765 (3.1%)

226 (3.8%)

539 (2.9%)

Other

635 (2.6%)

121 (2.1%)

514 (2.8%)

16,228 (65.8%)

3781 (64.2%)

12,447 (66.2%)

Diabetes

11,570 (47.0%)

2853 (48.5%)

8717 (46.5%)

CLD

3021 (12.7%)

641 (11.3%)

2380 (13.1%)

CAD

8077 (34.7%)

1765 (31.6%)

6312 (35.7%)

PVD

4306 (18.6%)

993 (17.9%)

3313 (18.8%)

CerebVD

2775 (11.6%)

610 (10.6%)

5156 (11.9%)

Comorbidities
Any

Cause of Primary Renal Disease
Glomerulonephritis

5494 (22.4%)

1446 (24.6%)

4048 (21.7%)

Diabetes

8803 (35.9%)

2265 (38.5%)

6538 (35.0%)

Hypertension

3262 (13.3%)

663 (11.3%)

2599 (13.9%)

Cystic disease

1751 (7.1%)

392 (6.7%)

1359 (7.3%)

Other

5242 (21.4%)

1117 (19.0%)

4125 (22.1%)

Facility HD

17,363 (70.4%)

5888 (73.8%)

13,015 (69.3%)

Home Therapies

6430 (26.1%)

1331 (22.6%)

5099 (27.1%)

Transplant

883 (3.6%)

209 (3.5%)

674 (3.6%)

First RRT modality

RRT modality at relocation or censoring
Facility HD

14,331 (58.1%)

3617 (61.4%)

10,714 (57.0%)

Home Therapies

5750 (23.3%)

1433 (24.3%)

4317 (23.0%)

Transplant

4595 (18.6%)

838 (14.2%)

3757 (20.0%)

Major

16,433 (66.6%)

3652 (62.6%)

12,781 (68.1%)

Inner Regional

4301 (17.5%)

805 (13.8%)

3496 (18.6%)

Urbanity

Outer Regional

2397 (9.7%)

599 (10.3%)

1798 (9.6%)

Remote

635 (2.6%)

214 (3.7%)

421 (2.2%)

Very Remote

843 (3.4%)

567 (9.7%)

276 (1.5%)

Data expressed as numbers (percentage) or mean (standard deviation)
All variables statistically significant (P < 0.05) except for PVD
Number (%) of missing data: 191 (0.8%) in race, 55 (0.2%) in diabetes status, 875 (3.5%) in chronic lung disease, 1397 (5.7%) in coronary artery disease, 1533
(6.2%) in peripheral vascular disease, 685 (2.8%) in cerebral vascular disease and 124 (0.5%) in cause of primary renal disease,
RRT Renal replacement therapy, HD Hemodialysis, ATSI Australia and Torres Strait Islander, MPI Maori Pacific Islander, CLD Chronic Lung Disease, CAD Coronary
artery disease, PVD Peripheral vascular disease, CerebVD Cerebrovascular disease

an independent risk for relocation with ATSI having a
SHR of 1.18 (95%CI 1.06–1.31, p = 0.002), being from a
remote region SHR 1.20 (95%CI 1.01–1.42, p = 0.034)
and very remote region SHR 3.51 (95%CI 3.05–4.04, p <
0.001).

Discussion
This is the first study to our knowledge describing geographical relocation in RRT patients, or any patient
group with chronic diseases, on a national level. We
found 23.9% of Australian RRT patients between 2005
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Table 2 Time from commencement of renal replacement to
relocation in relocation cohort
Time to relocation (years)
Relocation Group

1.6 [0.7, 3.4]

Gender
Male

1.7 [0.7, 3.4]

Female

1.6 [0.7, 3.3]

Race
Caucasian

1.9 [0.8, 3.6]

Asian

1.9 [0.9, 3.8]

ATSI

0.9 [0.4, 2.0]

MPI

1.7 [0.8, 2.9]

Other

1.8 [0.7, 3.2]

Comorbidity
Yes

1.5 [0.7, 3.0]

No

2.1 [0.9, 4.0]

Cause of Primary Renal Disease
Glomerulonephritis

1.9 [0.8, 3.8]

Diabetes

1.4 [0.6, 2.9]

Hypertension

1.7 [0.7, 3.3]

Cystic disease

2.4 [1.0, 4.2]

Other

1.7 [0.8, 3.4]

RRT at relocation
Facility HD

1.4 [0.6, 3.0]

Home Therapies

1.5 [0.7, 2.6]

Transplant

3.9 [2.3, 5.6]

Urbanity (from)
Major City

2.0 [0.9, 3.8]

Inner Regional

1.8 [0.8, 3.3]

Outer Regional

1.4 [0.7, 2.9]

Remote

1.3 [0.5, 2.5]

Very remote

0.6 [0.3, 1.2]

Urbanity (to)
Major City

1.9 [0.8, 3.6]

Inner Regional

1.8 [0.8, 3.5]

Outer Regional

1.1 [0.4, 2.4]

Remote

0.8 [0.4, 1.6]

Very remote

1.3 [0.7, 2.6]

Data expressed as median [intraquartile range]. Analysis by Log rank test for
study cohort
All variables statistically significant (P < 0.05)

and 2015 relocated, with a relocation incidence of 7.9
per 100 patient years. The proportion is higher than previous estimates of 5%, found in New South Wales in
Australia [17], and 15%, calculated from the difference
in age adjusted dialysis prevalence for urban vs rural
areas in a Japanese prefecture [4]. The increased proportion in our analysis likely resulted from including
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relocation within same remoteness of residence index
and examining a national registry over a 10-year period.
We highlighted the high relocation rate with increasing remoteness of residence index, with patients relocating more frequently and earlier from outer regional,
remote and very remote regions towards the major city
and inner regional areas. There are likely two main factors encouraging patients on RRT to geographically relocate; distance to a treatment centre and rurality.
Distance to a treatment centre with corresponding travel
time may add hours to an already lengthy treatment session. The higher incidence of relocation found in facility
HD compared to transplant is evidence of the burden
frequent travel for treatment could impose.
There is a clear decrease in prevalence of facility HD
with increased distance and travel time from a treatment
centre [3–6]. Prevalence is estimated to decrease by 5.5%
for every 10 min increase in travel time between residence and treatment centre [4] with prevalence significantly decreasing once travel time exceeds 15 min [5, 6].
An increase in the distance between patient residence
and treatment centre is also associated with an increase
in all-cause mortality [2, 18] and mortality from infection [18]. It was previously hypothesized that the decrease in prevalence with increasing travel time is a
result of increased mortality or withdrawals [2, 19], however our analysis supports the notion that patient relocation is also an important factor.
The second factor encouraging geographical relocation
is rurality. Australian rural patients with chronic diseases
undergo fewer diagnostic or therapeutic interventions
compared to urban centres, [10, 19–23] highlighting an
inequality in the provision of health services. This extends to rural RRT patients who have a lower health service utilisation, physician visits and proportion of
dialysis care [4, 5, 12, 17]. Australian RRT patients in regional districts, compared to major cities, have a lower
survival and higher risk of hospitalisation [12, 17] while
transplant patients in major cities are less likely to have
an acute rejection in the first 6 months post-transplant
[12]. While we found the absolute number of relocations
from rural areas to be low when compared to urban centres it does highlight the greater burden which RRT patients experience in these regions.
We found the risk of relocation among indigenous
population significant. Indigenous populations on RRT
remain susceptible to relocation given rural urbanity in
Canada [13] and Australia where relocation rates can
reach 50% in some communities [24]. The burden of illness suffered by native populations is further complicated by the difficulty in providing specialised tertiary
level care to geographically isolated small communities.
Geographic relocation for better access to specialised
treatment facilities does come with costs in the form of

Cheikh Hassan et al. BMC Nephrology

(2020) 21:249

Page 6 of 8

Table 3 Geographical relocation breakdown by direction of urbanity
Relocation to
Relocation from

Major City

Inner Regional

Outer Regional

Remote and Very Remote

Total

Major City

3268 (89.9%)

267 (7.3%)

73 (2.0%)

26 (0.7%)

3634 (62.8%)

Inner Regional

255 (31.9%)

464 (58.0%)

69 (8.6%)

12 (1.5%)

800 (13.8%)

Outer Regional

129 (21.9%)

125 (21.2%)

306 (51.9%)

27 (4.6%)

590 (10.2)

Remote and Very Remote

121 (15.9.0%)

32 (4.2%)

314 (41.3%)

83 (10.9%)

759 (13.1%)

Total

3773 (65.2%)

888 (15.4%)

762 (13.2%)

296 (5.1%)

5783

significant financial, cultural and psychological pressure
on the patient [15]. Patients may face family separation
and a lack of social support [13, 14] with significant detrimental effects on quality of life and ability and willingness to maintain treatment regimens [15]. Some patients
struggle with the idea of relocating by themselves and

are faced with the burden of relocating the whole family
[14]. A better understanding of the reasons behind relocation (personal or as a necessity for easier access to
treatment), factors influencing this decision and the impact it causes is needed. Such information would also inform health policy makers to enable optimization of

Table 4 Cox proportional hazard models and competing risk analysis, with death considered as a competing risk, examining risk
factors for relocation
Cox proportional hazards model
Univariate analysis
HR (95%CI)

P-value

Cox proportional hazards model
Multivariate analysis
aHR (95%CI)

P-value

Competing risk analysis
Multivariate analysis
SHR (95% CI)

P-value

Gender (M)

1.09 (1.03, 1.15)

0.001

–

–

–

–

Age (per decade)

0.87 (0.85, 0.88)

< 0.001

0.80 (0.78, 0.81)

0.75 (0.74, 0.77)

< 0.001

Race
Caucasian

Reference

–

Reference

–

Reference

–

Asian

1.07 (0.97, 1.17)

0.14

0.98 (0.89, 1.08)

0.73

1.06 (0.96, 1.16)

0.27

ATSI

2.99 (2.80, 3.20)

< 0.001

1.21 (1.09, 1.34)

0.001

1.18 (1.06, 1.31)

0.002

MPI

1.60 (1.40, 1.83)

< 0.001

1.07 (0.97, 1.27)

0.19

1.14 (0.99, 1.31)

0.052

Other

1.46 (1.22, 1.75)

< 0.001

1.25 (1.04, 1.50)

0.01

1.27 (1.07, 1.51)

0.006

1.18 (1.12,1.24)

< 0.001

–

–

–

–

Comorbidity (Yes)

Cause of Primary Renal Disease
Glomerulonephritis

Reference

< 0.001

–

–

–

–

Diabetes

1.27 (1.19, 1.37)

0.4

–

–

–

–

Hypertension

0.97 (0.88, 1.06)

< 0.001

–

–

–

–

Cystic disease

0.78 (0.70, 0.88)

0.1

–

–

–

–

Other

0.94 (0.87, 1.02)

–

–

–

–

–

Facility HD

Reference

–

Reference

–

Reference

–

Home Therapies

1.08 (1.02, 1.15)

0. 01

1.02 (0.96, 1.09)

0.54

0.97 (0.91, 1.04)

0.40

Transplant

0.37 (0.34, 0.39)

< 0.001

0.29 (0.27, 0.32)

< 0.001

0.37 (0.34, 0.40)

< 0.001

Reference

–

Reference

–

Reference

–

RRT at relocation

Urbanity (from)
Major City
Inner Regional

0.83 (0.77, 0.89)

< 0.001

0.83 (0.77, 0.90)

< 0.001

0.82 (0.76, 0.89)

< 0.001

Outer Regional

1.19 (1.01, 1.30)

< 0.001

1.03 (0.93, 1.13)

0.59

0.99 (0.91, 1.09)

0.98

Remote

1.86 (1.62, 2.13)

< 0.001

1.18 (1.01, 1.38)

0.04

1.20 (1.01, 1.42)

0.034

Very remote

6.46 (6.46, 7.06)

< 0.001

3.61 (3.20, 4.10)

< 0.001

3.51 (3.05, 4.04)

< 0.001

HR Hazard ration, aHR adjusted hazard ratio, SHR: subdistribution hazard ratio
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Fig. 1 Cumulative incidence graph showing time to relocation by (a) renal replacement therapy modality and (b) remoteness of residence index, using
mortality as a competing risk to calculate cumulative incidence function estimate. (Solid line for major city and dotted line for inner regional overlapping)

health resource allocation and development of efficient
treatment networks. This is particularly true in the
Australia where provision of coordinated comprehensive
care for RRT patients can be a challenge in the setting
of a large landmass and low population density with a
sizable rural population.
Our study has several limitations. The data entered in
the ANZDATA registry is submitted by each treatment
centre, and the registry does not verify the accuracy of
these reports or missing information. The dependency
on postcode change to define a relocation likely underestimated the magnitude of our results. Since ANZDATA
registry identified relocations at the end of the calendar
year, the actual time to relocation is likely shorter. Our
study was an observational analysis hence we could not
prove direction of causality. We were also unable to

include patients who relocated prior to commencing
RRT or patients who were managed conservatively for
ESRD. Finally, besides distance to treating centre, other
psychosocial factors may influence the decision for relocation including patient and family supports, housing
instability, financial security, and need for home care
which we were unable to explore. Future studies are required to explore these factors.

Conclusion
We determined the relocation incidence and prevalence
in RRT in Australia. We also established factors associated with higher relocation rates. Further studies could
be undertaken to determine the cause for relocation and
the effect relocation imposes on quality of life and
mortality.
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